Short answer
IDEAYA Biosciences, Inc. (IDYA) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10M (down 95.1% year over year) with net income of −$126M.
Q3 2026 key financials · XBRL
- Revenue
- $10M
- −95.1% YoY · +15.6% QoQ
- Net income
- −$126M
- −205.5% YoY · −11.8% QoQ
- Operating margin
- -1343.7%
- EPS (diluted)
- −$1.23
- −191.1% YoY · −0.8% QoQ
Source: XBRL data from the IDEAYA Biosciences, Inc. (IDYA) Q3 2026 10-Q on SEC EDGAR. USD.
IDEAYA Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly collaboration revenue $10.2M, up 16% from $8.9M in Q2 2026
- Q3 net loss $125.7M, operating loss $137.6M, no product revenue
- Darovasertib highest Q3 clinical spend $35.1M, IDE161 lowest at $1.4M
- Cash, equivalents and marketable securities approximately $1.15B; operating cash used $256.9M
- Financing cash $364.1M, including $323.4M net follow-on offering proceeds; funding expected for at least twelve months
Risk Factors
- No material changes to risk factors disclosed in the February 17, 2026 Annual Report
- Carried-forward risks include potential adverse effects on business, financial condition, and future results
- Quarterly filing provides no newly triggered regulatory, operational, competitive, or financial risk વિગતો
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IDEAYA Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.